nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—Hypomagnesaemia—Vandetanib—thyroid cancer	0.0288	0.0381	CcSEcCtD
Conivaptan—Electrocardiogram ST segment depression—Epirubicin—thyroid cancer	0.0201	0.0266	CcSEcCtD
Conivaptan—Electrocardiogram ST segment depression—Doxorubicin—thyroid cancer	0.0186	0.0246	CcSEcCtD
Conivaptan—AVPR2—Vasopressin regulates renal water homeostasis via Aquaporins—PRKAR1A—thyroid cancer	0.0171	0.0705	CbGpPWpGaD
Conivaptan—AVPR2—Arf6 trafficking events—TSHR—thyroid cancer	0.0162	0.0668	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—CALCB—thyroid cancer	0.0161	0.0664	CbGpPWpGaD
Conivaptan—Sepsis—Vandetanib—thyroid cancer	0.0159	0.021	CcSEcCtD
Conivaptan—AVPR2—Aquaporin-mediated transport—PRKAR1A—thyroid cancer	0.0149	0.0615	CbGpPWpGaD
Conivaptan—Atrial fibrillation—Vandetanib—thyroid cancer	0.014	0.0185	CcSEcCtD
Conivaptan—Cardiac failure—Vandetanib—thyroid cancer	0.0136	0.018	CcSEcCtD
Conivaptan—Hypoglycaemia—Vandetanib—thyroid cancer	0.0136	0.018	CcSEcCtD
Conivaptan—Hyponatraemia—Vandetanib—thyroid cancer	0.0133	0.0176	CcSEcCtD
Conivaptan—Dehydration—Vandetanib—thyroid cancer	0.0124	0.0163	CcSEcCtD
Conivaptan—Hypokalaemia—Vandetanib—thyroid cancer	0.0121	0.016	CcSEcCtD
Conivaptan—AVPR1A—Peptide GPCRs—TSHR—thyroid cancer	0.0114	0.0468	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—TSHR—thyroid cancer	0.0113	0.0464	CbGpPWpGaD
Conivaptan—Pollakiuria—Vandetanib—thyroid cancer	0.0106	0.014	CcSEcCtD
Conivaptan—Hyperglycaemia—Vandetanib—thyroid cancer	0.0104	0.0137	CcSEcCtD
Conivaptan—Pneumonia—Vandetanib—thyroid cancer	0.0103	0.0136	CcSEcCtD
Conivaptan—Infestation NOS—Vandetanib—thyroid cancer	0.0102	0.0135	CcSEcCtD
Conivaptan—Infestation—Vandetanib—thyroid cancer	0.0102	0.0135	CcSEcCtD
Conivaptan—Urinary tract infection—Vandetanib—thyroid cancer	0.00995	0.0131	CcSEcCtD
Conivaptan—Haematuria—Vandetanib—thyroid cancer	0.00976	0.0129	CcSEcCtD
Conivaptan—Cardiac failure—Sorafenib—thyroid cancer	0.00919	0.0121	CcSEcCtD
Conivaptan—Urinary tract disorder—Vandetanib—thyroid cancer	0.00908	0.012	CcSEcCtD
Conivaptan—Urethral disorder—Vandetanib—thyroid cancer	0.00901	0.0119	CcSEcCtD
Conivaptan—Hyponatraemia—Sorafenib—thyroid cancer	0.009	0.0119	CcSEcCtD
Conivaptan—Cardiac disorder—Vandetanib—thyroid cancer	0.00853	0.0113	CcSEcCtD
Conivaptan—Angiopathy—Vandetanib—thyroid cancer	0.00834	0.011	CcSEcCtD
Conivaptan—Dehydration—Sorafenib—thyroid cancer	0.00834	0.011	CcSEcCtD
Conivaptan—Mediastinal disorder—Vandetanib—thyroid cancer	0.00829	0.0109	CcSEcCtD
Conivaptan—Hypokalaemia—Sorafenib—thyroid cancer	0.00816	0.0108	CcSEcCtD
Conivaptan—Mental disorder—Vandetanib—thyroid cancer	0.00805	0.0106	CcSEcCtD
Conivaptan—Malnutrition—Vandetanib—thyroid cancer	0.008	0.0106	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—TSHR—thyroid cancer	0.00746	0.0307	CbGpPWpGaD
Conivaptan—Hypomagnesaemia—Epirubicin—thyroid cancer	0.00718	0.00949	CcSEcCtD
Conivaptan—Oral candidiasis—Epirubicin—thyroid cancer	0.00718	0.00949	CcSEcCtD
Conivaptan—Pneumonia—Sorafenib—thyroid cancer	0.00695	0.00918	CcSEcCtD
Conivaptan—Hypertension—Vandetanib—thyroid cancer	0.00691	0.00913	CcSEcCtD
Conivaptan—Infestation NOS—Sorafenib—thyroid cancer	0.00691	0.00912	CcSEcCtD
Conivaptan—Infestation—Sorafenib—thyroid cancer	0.00691	0.00912	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00677	0.00894	CcSEcCtD
Conivaptan—Dry mouth—Vandetanib—thyroid cancer	0.00666	0.0088	CcSEcCtD
Conivaptan—Oral candidiasis—Doxorubicin—thyroid cancer	0.00665	0.00878	CcSEcCtD
Conivaptan—Hypomagnesaemia—Doxorubicin—thyroid cancer	0.00665	0.00878	CcSEcCtD
Conivaptan—Infection—Vandetanib—thyroid cancer	0.00649	0.00857	CcSEcCtD
Conivaptan—Nervous system disorder—Vandetanib—thyroid cancer	0.00641	0.00846	CcSEcCtD
Conivaptan—Skin disorder—Vandetanib—thyroid cancer	0.00634	0.00838	CcSEcCtD
Conivaptan—Urinary tract disorder—Sorafenib—thyroid cancer	0.00612	0.00809	CcSEcCtD
Conivaptan—Urethral disorder—Sorafenib—thyroid cancer	0.00608	0.00803	CcSEcCtD
Conivaptan—Insomnia—Vandetanib—thyroid cancer	0.00591	0.0078	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CALCB—thyroid cancer	0.00589	0.0243	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CALCB—thyroid cancer	0.00585	0.0241	CbGpPWpGaD
Conivaptan—Cardiac disorder—Sorafenib—thyroid cancer	0.00576	0.0076	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00564	0.00745	CcSEcCtD
Conivaptan—Angiopathy—Sorafenib—thyroid cancer	0.00563	0.00743	CcSEcCtD
Conivaptan—Mediastinal disorder—Sorafenib—thyroid cancer	0.00559	0.00738	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—CALCA—thyroid cancer	0.00559	0.023	CbGpPWpGaD
Conivaptan—Pain—Vandetanib—thyroid cancer	0.00559	0.00738	CcSEcCtD
Conivaptan—Constipation—Vandetanib—thyroid cancer	0.00559	0.00738	CcSEcCtD
Conivaptan—Mental disorder—Sorafenib—thyroid cancer	0.00543	0.00718	CcSEcCtD
Conivaptan—Malnutrition—Sorafenib—thyroid cancer	0.0054	0.00713	CcSEcCtD
Conivaptan—Erythema—Sorafenib—thyroid cancer	0.0054	0.00713	CcSEcCtD
Conivaptan—Body temperature increased—Vandetanib—thyroid cancer	0.00516	0.00682	CcSEcCtD
Conivaptan—Anaemia—Sorafenib—thyroid cancer	0.00499	0.00659	CcSEcCtD
Conivaptan—Hypertension—Sorafenib—thyroid cancer	0.00466	0.00616	CcSEcCtD
Conivaptan—Pruritus—Vandetanib—thyroid cancer	0.00462	0.0061	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00456	0.00603	CcSEcCtD
Conivaptan—Dry mouth—Sorafenib—thyroid cancer	0.00449	0.00594	CcSEcCtD
Conivaptan—Diarrhoea—Vandetanib—thyroid cancer	0.00447	0.0059	CcSEcCtD
Conivaptan—Infection—Sorafenib—thyroid cancer	0.00438	0.00578	CcSEcCtD
Conivaptan—Candida infection—Epirubicin—thyroid cancer	0.00436	0.00576	CcSEcCtD
Conivaptan—Nervous system disorder—Sorafenib—thyroid cancer	0.00432	0.00571	CcSEcCtD
Conivaptan—Skin disorder—Sorafenib—thyroid cancer	0.00428	0.00565	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—SST—thyroid cancer	0.00415	0.0171	CbGpPWpGaD
Conivaptan—Vomiting—Vandetanib—thyroid cancer	0.00415	0.00549	CcSEcCtD
Conivaptan—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00413	0.017	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—SST—thyroid cancer	0.00412	0.017	CbGpPWpGaD
Conivaptan—Headache—Vandetanib—thyroid cancer	0.00409	0.0054	CcSEcCtD
Conivaptan—Candida infection—Doxorubicin—thyroid cancer	0.00403	0.00533	CcSEcCtD
Conivaptan—Sepsis—Epirubicin—thyroid cancer	0.00396	0.00523	CcSEcCtD
Conivaptan—Nausea—Vandetanib—thyroid cancer	0.00388	0.00512	CcSEcCtD
Conivaptan—Phlebitis—Epirubicin—thyroid cancer	0.00385	0.00508	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0038	0.00502	CcSEcCtD
Conivaptan—Constipation—Sorafenib—thyroid cancer	0.00377	0.00498	CcSEcCtD
Conivaptan—Pain—Sorafenib—thyroid cancer	0.00377	0.00498	CcSEcCtD
Conivaptan—Sepsis—Doxorubicin—thyroid cancer	0.00366	0.00484	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00358	0.0148	CbGpPWpGaD
Conivaptan—Phlebitis—Doxorubicin—thyroid cancer	0.00356	0.0047	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00356	0.0146	CbGpPWpGaD
Conivaptan—Body temperature increased—Sorafenib—thyroid cancer	0.00348	0.0046	CcSEcCtD
Conivaptan—Cardiac failure—Epirubicin—thyroid cancer	0.00339	0.00448	CcSEcCtD
Conivaptan—Hypoglycaemia—Epirubicin—thyroid cancer	0.00339	0.00448	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CALCB—thyroid cancer	0.00333	0.0137	CbGpPWpGaD
Conivaptan—Hyponatraemia—Epirubicin—thyroid cancer	0.00333	0.00439	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—CALCB—thyroid cancer	0.00331	0.0136	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00328	0.0135	CbGpPWpGaD
Conivaptan—Cardiac failure—Doxorubicin—thyroid cancer	0.00314	0.00415	CcSEcCtD
Conivaptan—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00314	0.00415	CcSEcCtD
Conivaptan—Pruritus—Sorafenib—thyroid cancer	0.00312	0.00412	CcSEcCtD
Conivaptan—Dehydration—Epirubicin—thyroid cancer	0.00308	0.00407	CcSEcCtD
Conivaptan—Hyponatraemia—Doxorubicin—thyroid cancer	0.00308	0.00407	CcSEcCtD
Conivaptan—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00303	0.004	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CALCB—thyroid cancer	0.00302	0.0125	CbGpPWpGaD
Conivaptan—Hypokalaemia—Epirubicin—thyroid cancer	0.00302	0.00398	CcSEcCtD
Conivaptan—Diarrhoea—Sorafenib—thyroid cancer	0.00301	0.00398	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CALCB—thyroid cancer	0.003	0.0124	CbGpPWpGaD
Conivaptan—Dehydration—Doxorubicin—thyroid cancer	0.00285	0.00377	CcSEcCtD
Conivaptan—Vomiting—Sorafenib—thyroid cancer	0.0028	0.0037	CcSEcCtD
Conivaptan—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.0028	0.0037	CcSEcCtD
Conivaptan—Hypokalaemia—Doxorubicin—thyroid cancer	0.00279	0.00368	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00279	0.0115	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00277	0.0114	CbGpPWpGaD
Conivaptan—Headache—Sorafenib—thyroid cancer	0.00276	0.00365	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—TSHR—thyroid cancer	0.00273	0.0112	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—TSHR—thyroid cancer	0.00271	0.0112	CbGpPWpGaD
Conivaptan—Pollakiuria—Epirubicin—thyroid cancer	0.00265	0.00349	CcSEcCtD
Conivaptan—Nausea—Sorafenib—thyroid cancer	0.00262	0.00346	CcSEcCtD
Conivaptan—Hyperglycaemia—Epirubicin—thyroid cancer	0.00258	0.00341	CcSEcCtD
Conivaptan—Pneumonia—Epirubicin—thyroid cancer	0.00257	0.00339	CcSEcCtD
Conivaptan—Infestation NOS—Epirubicin—thyroid cancer	0.00255	0.00337	CcSEcCtD
Conivaptan—Infestation—Epirubicin—thyroid cancer	0.00255	0.00337	CcSEcCtD
Conivaptan—Urinary tract infection—Epirubicin—thyroid cancer	0.00248	0.00328	CcSEcCtD
Conivaptan—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00247	0.0102	CbGpPWpGaD
Conivaptan—Pollakiuria—Doxorubicin—thyroid cancer	0.00245	0.00323	CcSEcCtD
Conivaptan—Haematuria—Epirubicin—thyroid cancer	0.00243	0.00322	CcSEcCtD
Conivaptan—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00239	0.00316	CcSEcCtD
Conivaptan—Pneumonia—Doxorubicin—thyroid cancer	0.00238	0.00314	CcSEcCtD
Conivaptan—Infestation NOS—Doxorubicin—thyroid cancer	0.00236	0.00312	CcSEcCtD
Conivaptan—Infestation—Doxorubicin—thyroid cancer	0.00236	0.00312	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—PTCH1—thyroid cancer	0.00232	0.00955	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—PTCH1—thyroid cancer	0.0023	0.00948	CbGpPWpGaD
Conivaptan—Urinary tract infection—Doxorubicin—thyroid cancer	0.0023	0.00303	CcSEcCtD
Conivaptan—Urinary tract disorder—Epirubicin—thyroid cancer	0.00226	0.00299	CcSEcCtD
Conivaptan—Oedema peripheral—Epirubicin—thyroid cancer	0.00226	0.00298	CcSEcCtD
Conivaptan—Haematuria—Doxorubicin—thyroid cancer	0.00225	0.00297	CcSEcCtD
Conivaptan—Urethral disorder—Epirubicin—thyroid cancer	0.00225	0.00297	CcSEcCtD
Conivaptan—Cardiac disorder—Epirubicin—thyroid cancer	0.00213	0.00281	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—SST—thyroid cancer	0.00212	0.00874	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—SST—thyroid cancer	0.00211	0.00867	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—CP—thyroid cancer	0.0021	0.00863	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.0021	0.00863	CbGpPWpGaD
Conivaptan—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00209	0.00277	CcSEcCtD
Conivaptan—Oedema peripheral—Doxorubicin—thyroid cancer	0.00209	0.00276	CcSEcCtD
Conivaptan—Angiopathy—Epirubicin—thyroid cancer	0.00208	0.00275	CcSEcCtD
Conivaptan—Urethral disorder—Doxorubicin—thyroid cancer	0.00208	0.00275	CcSEcCtD
Conivaptan—Mediastinal disorder—Epirubicin—thyroid cancer	0.00207	0.00273	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00206	0.00849	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CALCA—thyroid cancer	0.00204	0.00841	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CALCA—thyroid cancer	0.00203	0.00835	CbGpPWpGaD
Conivaptan—Mental disorder—Epirubicin—thyroid cancer	0.00201	0.00265	CcSEcCtD
Conivaptan—Malnutrition—Epirubicin—thyroid cancer	0.002	0.00264	CcSEcCtD
Conivaptan—Erythema—Epirubicin—thyroid cancer	0.002	0.00264	CcSEcCtD
Conivaptan—Cardiac disorder—Doxorubicin—thyroid cancer	0.00197	0.0026	CcSEcCtD
Conivaptan—Angiopathy—Doxorubicin—thyroid cancer	0.00192	0.00254	CcSEcCtD
Conivaptan—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00191	0.00252	CcSEcCtD
Conivaptan—Mental disorder—Doxorubicin—thyroid cancer	0.00186	0.00245	CcSEcCtD
Conivaptan—Malnutrition—Doxorubicin—thyroid cancer	0.00185	0.00244	CcSEcCtD
Conivaptan—Erythema—Doxorubicin—thyroid cancer	0.00185	0.00244	CcSEcCtD
Conivaptan—Anaemia—Epirubicin—thyroid cancer	0.00184	0.00244	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CALCB—thyroid cancer	0.00179	0.00736	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CALCB—thyroid cancer	0.00177	0.0073	CbGpPWpGaD
Conivaptan—Hypertension—Epirubicin—thyroid cancer	0.00172	0.00228	CcSEcCtD
Conivaptan—Anaemia—Doxorubicin—thyroid cancer	0.00171	0.00225	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—TRIM33—thyroid cancer	0.00169	0.00697	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00169	0.00223	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—TRIM33—thyroid cancer	0.00168	0.00692	CbGpPWpGaD
Conivaptan—Dry mouth—Epirubicin—thyroid cancer	0.00166	0.00219	CcSEcCtD
Conivaptan—Confusional state—Epirubicin—thyroid cancer	0.00164	0.00217	CcSEcCtD
Conivaptan—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00163	0.0067	CbGpPWpGaD
Conivaptan—Infection—Epirubicin—thyroid cancer	0.00162	0.00214	CcSEcCtD
Conivaptan—Nervous system disorder—Epirubicin—thyroid cancer	0.0016	0.00211	CcSEcCtD
Conivaptan—Hypertension—Doxorubicin—thyroid cancer	0.00159	0.00211	CcSEcCtD
Conivaptan—Skin disorder—Epirubicin—thyroid cancer	0.00158	0.00209	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00157	0.00646	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00156	0.00206	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—TSHR—thyroid cancer	0.00154	0.00635	CbGpPWpGaD
Conivaptan—Dry mouth—Doxorubicin—thyroid cancer	0.00154	0.00203	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—TSHR—thyroid cancer	0.00153	0.0063	CbGpPWpGaD
Conivaptan—Hypotension—Epirubicin—thyroid cancer	0.00152	0.00201	CcSEcCtD
Conivaptan—Confusional state—Doxorubicin—thyroid cancer	0.00152	0.00201	CcSEcCtD
Conivaptan—Infection—Doxorubicin—thyroid cancer	0.0015	0.00198	CcSEcCtD
Conivaptan—Nervous system disorder—Doxorubicin—thyroid cancer	0.00148	0.00195	CcSEcCtD
Conivaptan—Insomnia—Epirubicin—thyroid cancer	0.00147	0.00195	CcSEcCtD
Conivaptan—Skin disorder—Doxorubicin—thyroid cancer	0.00146	0.00193	CcSEcCtD
Conivaptan—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.00144	0.00591	CbGpPWpGaD
Conivaptan—Hypotension—Doxorubicin—thyroid cancer	0.00141	0.00186	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00141	0.00186	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—TSHR—thyroid cancer	0.0014	0.00577	CbGpPWpGaD
Conivaptan—Constipation—Epirubicin—thyroid cancer	0.00139	0.00184	CcSEcCtD
Conivaptan—Pain—Epirubicin—thyroid cancer	0.00139	0.00184	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—TSHR—thyroid cancer	0.00139	0.00572	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00138	0.00567	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00137	0.00563	CbGpPWpGaD
Conivaptan—Insomnia—Doxorubicin—thyroid cancer	0.00136	0.0018	CcSEcCtD
Conivaptan—Feeling abnormal—Epirubicin—thyroid cancer	0.00134	0.00177	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00132	0.00543	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.0013	0.00172	CcSEcCtD
Conivaptan—Constipation—Doxorubicin—thyroid cancer	0.00129	0.0017	CcSEcCtD
Conivaptan—Pain—Doxorubicin—thyroid cancer	0.00129	0.0017	CcSEcCtD
Conivaptan—Body temperature increased—Epirubicin—thyroid cancer	0.00129	0.0017	CcSEcCtD
Conivaptan—Feeling abnormal—Doxorubicin—thyroid cancer	0.00124	0.00164	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—SST—thyroid cancer	0.0012	0.00494	CbGpPWpGaD
Conivaptan—Body temperature increased—Doxorubicin—thyroid cancer	0.00119	0.00157	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—PTCH1—thyroid cancer	0.00119	0.0049	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—SST—thyroid cancer	0.00119	0.0049	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PTCH1—thyroid cancer	0.00118	0.00487	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00118	0.00484	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CALCA—thyroid cancer	0.00115	0.00475	CbGpPWpGaD
Conivaptan—Pruritus—Epirubicin—thyroid cancer	0.00115	0.00152	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—CALCA—thyroid cancer	0.00115	0.00472	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TCF7L1—thyroid cancer	0.00113	0.00465	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TCF7L1—thyroid cancer	0.00112	0.00462	CbGpPWpGaD
Conivaptan—Diarrhoea—Epirubicin—thyroid cancer	0.00111	0.00147	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—SST—thyroid cancer	0.00109	0.00448	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—SST—thyroid cancer	0.00108	0.00445	CbGpPWpGaD
Conivaptan—Pruritus—Doxorubicin—thyroid cancer	0.00107	0.00141	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CALCA—thyroid cancer	0.00105	0.00432	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CALCA—thyroid cancer	0.00104	0.00428	CbGpPWpGaD
Conivaptan—Vomiting—Epirubicin—thyroid cancer	0.00104	0.00137	CcSEcCtD
Conivaptan—Diarrhoea—Doxorubicin—thyroid cancer	0.00103	0.00136	CcSEcCtD
Conivaptan—Headache—Epirubicin—thyroid cancer	0.00102	0.00135	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.00101	0.00417	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000985	0.00405	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000979	0.00403	CbGpPWpGaD
Conivaptan—Nausea—Epirubicin—thyroid cancer	0.000967	0.00128	CcSEcCtD
Conivaptan—Vomiting—Doxorubicin—thyroid cancer	0.000958	0.00127	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CDK1—thyroid cancer	0.000949	0.00391	CbGpPWpGaD
Conivaptan—Headache—Doxorubicin—thyroid cancer	0.000944	0.00125	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CDK1—thyroid cancer	0.000942	0.00388	CbGpPWpGaD
Conivaptan—Nausea—Doxorubicin—thyroid cancer	0.000895	0.00118	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000861	0.00354	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TSHR—thyroid cancer	0.000827	0.00341	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TSHR—thyroid cancer	0.000821	0.00338	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000814	0.00335	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000808	0.00333	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000798	0.00329	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MEN1—thyroid cancer	0.000778	0.0032	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MEN1—thyroid cancer	0.000772	0.00318	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTCH1—thyroid cancer	0.000703	0.0029	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTCH1—thyroid cancer	0.000698	0.00287	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SST—thyroid cancer	0.000643	0.00265	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SST—thyroid cancer	0.000639	0.00263	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CALCA—thyroid cancer	0.000619	0.00255	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CALCA—thyroid cancer	0.000615	0.00253	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDK1—thyroid cancer	0.000561	0.00231	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDK1—thyroid cancer	0.000557	0.00229	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NRG1—thyroid cancer	0.00045	0.00185	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NRG1—thyroid cancer	0.000447	0.00184	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000424	0.00175	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TERT—thyroid cancer	0.000404	0.00166	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TERT—thyroid cancer	0.000401	0.00165	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HIF1A—thyroid cancer	0.000386	0.00159	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HIF1A—thyroid cancer	0.000384	0.00158	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—NRAS—thyroid cancer	0.00034	0.0014	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—NRAS—thyroid cancer	0.000338	0.00139	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—BRAF—thyroid cancer	0.00032	0.00132	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—BRAF—thyroid cancer	0.000318	0.00131	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000311	0.00128	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—KRAS—thyroid cancer	0.000293	0.00121	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—KRAS—thyroid cancer	0.000291	0.0012	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000265	0.00109	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HRAS—thyroid cancer	0.000249	0.00103	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000249	0.00103	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HRAS—thyroid cancer	0.000247	0.00102	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—AKT1—thyroid cancer	0.000242	0.000997	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AKT1—thyroid cancer	0.00024	0.00099	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCND1—thyroid cancer	0.000234	0.000961	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCND1—thyroid cancer	0.000232	0.000954	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTEN—thyroid cancer	0.000225	0.000928	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTEN—thyroid cancer	0.000224	0.000921	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AKT1—thyroid cancer	0.00022	0.000905	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AKT1—thyroid cancer	0.000218	0.000899	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NRAS—thyroid cancer	0.000201	0.000828	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000201	0.000826	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NRAS—thyroid cancer	0.0002	0.000822	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KRAS—thyroid cancer	0.000173	0.000712	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KRAS—thyroid cancer	0.000172	0.000707	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—thyroid cancer	0.000154	0.000633	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—thyroid cancer	0.000153	0.000629	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HRAS—thyroid cancer	0.000147	0.000606	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HRAS—thyroid cancer	0.000146	0.000601	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AKT1—thyroid cancer	0.00013	0.000535	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AKT1—thyroid cancer	0.000129	0.000531	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TPR—thyroid cancer	0.000115	0.000475	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	0.000113	0.000467	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC5A5—thyroid cancer	8.63e-05	0.000355	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—RXRA—thyroid cancer	7.25e-05	0.000298	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PPARG—thyroid cancer	4.58e-05	0.000188	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.6e-05	0.000148	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTEN—thyroid cancer	3.14e-05	0.000129	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AKT1—thyroid cancer	1.81e-05	7.45e-05	CbGpPWpGaD
